Features of detection of latent tuberculosis infection in patients with inflammatory intestinal diseases


  • Gylystan BABAEVA Research Institute of Pulmonary Diseases of the Ministry of Health; Azerbaijan State Institute of Advanced Medical Training named after A.Aliyev
  • KENIUL KERIMOVA Research Institute of Pulmonary Diseases of the Ministry of Health; Azerbaijan State Institute of Advanced Medical Training named after A.Aliyev
  • Gamar AHMEDZADE Research Institute of Pulmonary Diseases of the Ministry of Health; Azerbaijan State Institute of Advanced Medical Training named after A.Aliyev




inflammatory bowel diseases, tuberculosis, latent tuberculosis infection, gastrointestinal tuberculosis, abdominal tuberculosis


A quarter of the world’s population has latent tuberculosis infection (LTBI). Systemic immunosuppression is a risk factor for the reactivation of LTBI and the development of active tuberculosis, and such reactivation is associated with a substantial risk of morbidity and mortality. Despite the growing global prevalence of inflammatory bowel diseases (IBD) and the use of immunosuppressive therapies, current recommendations for LTBI testing and treatment in IBD patients lack a systematic approach due to a lack of evidence. Currently, the main challenge in accurately diagnosing inflammatorybowel diseases (IBD) is the high prevalence of conditions that lead to intestinal lesions mimicking IBD.

Author Biographies

Gylystan BABAEVA, Research Institute of Pulmonary Diseases of the Ministry of Health; Azerbaijan State Institute of Advanced Medical Training named after A.Aliyev

Candidate of Medical Sciences

KENIUL KERIMOVA, Research Institute of Pulmonary Diseases of the Ministry of Health; Azerbaijan State Institute of Advanced Medical Training named after A.Aliyev

Candidate of Medical Sciences

Gamar AHMEDZADE, Research Institute of Pulmonary Diseases of the Ministry of Health; Azerbaijan State Institute of Advanced Medical Training named after A.Aliyev

Candidate of Medical Sciences


Agarwal S, Das SK, Agarwal GG, Srivastava R. Steroids decrease prevalence of positive tuberculin skin test in rheumatoid arthritis: implications on anti-TNF therapies. Interdiscip Perspect Infect Dis 2014; 2014:430134, 1, 5.

Amanullah F., Ashfaq M., Khowaja S., Parekh A., Salahuddin N., Lotia-Farrukh I., Khan A.J., Becerra M.C.High tuberculosis prevalence in children exposed at home to drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2014; 18(5): 520– 7.

Australian Government Department of Health. National position statement for the management of latent tuberculosis infection. Australian Government Department of Health. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cdi4103-d.

Ayles H., Schaap A., Nota A., Sismanidis Ch., Tembwe R., Haas P.D., Muyoyeta M., Beyers N., Godfrey-Faussett P. Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV. PLoS ONE. 2009; 4(5):e5602.

Bastian I, Shephard L, Lumb R. Revised guidelines for Australian laboratories performing mycobacteriology testing. Commun Dis Intellig. 2021; 44. http://dx.doi.org/10.33321/cdi.2020.44.2

Beglinger Ch., Dudler J., Mottet Ch., Nicod L., Seibold F., Villiger P.M., Zellweger J.-P. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly. 2007; 137(43–44): 620–2.

British Thoracic Society standards of care C. BTS recommendations for assessing risk and for managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005; 60(10): 800–5.

Brown J., Kumar K., Reading J., Harvey J., Murthy S., Capocci S., Hopkins S., Seneviratne S., Cropley I., Lipman M. Frequency and significance of indeterminate and borderline quantiferon gold TB IGRA results. Eur Respir J. 2017; 50(4): 1701267.

Cantini F., Nannini C., Niccoli L., Iannone Fl., Delogu G., Garlaschi G., Sanduzzi A., Matucci A., Prignano F., Conversano M., Goletti D., SAFEBIO (Italian Multidisciplinary Task Force for Screening of Tuberculosis Before and During Biologic Therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015; 14(6): 503– 9.

Сhekich C., Aslan F., Vatansever S., Topal F., Yüksel E.S., Alper E., Dallı A., Ünsal B. Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy. Ann Gastroenterol. 2015; 28(2): 241– 6.

Corbett E.L., Zezai A., Cheung Y.B., Bandason T., Dauya E., Munyati Sh.S., Butterworth A.E., Rusikaniko S., Churchyard G.J., Mungofa St., Hayes R.J., Mason P.R. Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull World Health Organ. 2010; 88(1): 13– 21.

Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008; 59(2): 209– 17.

Dong Il Park Tadakazu Hisamatsu Tadakazu Hisamatsu Minhu Chen et al. Asian organization forCrohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment. Intestinal Res. 2018;16(1):4-16.

Duarte R., Campainha S., Cotter J., Rosa B., Varela P., Correia A., Canhão H., Fonseca J. E. Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy. Acta Reumatol Port. 2012; 37(3): 253– 9.

Fehily S.R., Al-Ani A.H., Abdelmalak J., Rentch C., Zhang E., Denholm J.., Johnson D., Ng S. C., Sharma V., Rubin D.T., Gibson P.R., Christensen B. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression— risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022;56: 6–27.

Fonseca J.E., Lucas H., Canhão H., Duarte R., Santos M.J., Villar M., Faustino A., Raymundo E. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors March 2008 update. Rev Port Pneumol. 2008; 14(2): 271– 83.

Ford A.C., Bernstein Ch.N., Khan Kh.J., Abreu M.T., Marshall J.K., et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106(4): 590– 9.

Fujikawa A., Fujii T., Mimura S., Takahashi R., Sakai M., et al. Tuberculosis contact investigation using interferon-gamma release assay with chest x-ray and computed tomography. PLoS ONE. 2014; 9(1):e85612.

Hakimian S, Popov Y, Rupawala A, Salomon-Escoto K, Hatch S, et al. The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation. Biol Targets Ther. 2018; 12: 61– 67. http://dx.doi.org/10.2147/btt.s150958

Hodkinson B, Van Duuren E, Pettipher C, Kalla A, South African R, Arthritis A. South African recommendations for the management of rheumatoid arthritis: an algorithm for the standard of care in 2013. S Afr Med J. 2013; 103(8 Pt 2): 576– 85.

Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016; 13(10):e1002152.

Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Care Res. 2006; 55(1): 19– 26.

Kavanagh PM, Gilmartin JJ, O’Donnell J, O’Flanagan D. Tumour necrosis factor-alpha and tuberculosis: guidance from the national TB advisory Committee. Ir Med J. 2008; 101(1): 6– 7.

Keith PJ, Wetter DA, Wilson JW, Lehman JS. Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses. Br J Dermatol. 2014; 171(6): 1307– 17.

Koike R, Takeuchi T, Eguchi K, Miyasaka N. Japan College of R. update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007; 17(6): 451– 8.

Kumar P, Vuyyuru SK, Kante B, Sahu P, Goyal S, Madhu D. et al. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region. Aliment Pharmacol Ther. 2022; 55 (11):1431-1440.

Lewinsohn D.M., Leonard M.K., LoBue Ph.A.., Cohn D.L., Daley Ch.L., Desmond E., Keane J., Lewinsohn D.A., Loeffler A.M., Mazurek G.H., O’Brien R.J., Pai M., Richeldi L., Salfinger M., Shinnick T.M., Sterling T.R.,Warshauer D.M., Woods G.L. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017; 64(2): 111– 5.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: Management of Crohn’s disease in adults. Am J Gastroenterol. 2018; 113 (4): 481– 517.

Lorenzetti R., Zullo A., Ridola L., Diamanti A.P., Laganà B., Gatta L., Migliore A., Armuzzi A., Hassan C., Bruzzese V. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med. 2014; 46(7): 547– 54.

Mazurek G.H., Jereb J., Vernon A., LoBue Ph., Goldberg St., Castro K.; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection United States, 2010. MMWR Recomm Rep. 2010; 59(RR-5): 1– 25.

Menzies NA, Cohen T, Salomon JA. Evidence sources on the natural history of latent tuberculosis infection. Lancet Infect Dis. 2018; 18(8): 834– 5.

Mir Viladrich I., Tello E.D., Solano-López G., Longo Fr.J.L., Samso C.T., Martínez P.S., Lacasa X.M., Gasalla M.G., Sargatal J.D., Guillén-Arias M., García J.M. Consensus document on prevention and treatment of tuberculosis in patients for biological treatment. Arch Bronconeumol. 2016; 52(1): 36– 45.

Mok CC, Tam LS, Chan TH, Lee GK, Li EK. Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol. 2011; 30 (3): 303– 12.

Nordgaard-Lassen I., Dahlerup J.F., Belard E., Gerstoft J., Kjeldsen J., Kragballe K., Ravn P., Sørensen I.J., Theede K., Tjellesen L. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012; 59 (C4480): 2011.

Papay P., Eser Al., Winkler S., Frantal S., Primas Ch., Miehsler W., Novacek G., Vogelsang H., Dejaco Cl., Reinisch W. Factors impacting the results of interferon-gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2011; 17(1): 84– 90.

Piccazzo R, Paparo F, Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. J Rheumatol Suppl. 2014; 91: 32– 40.

Qumseya BJ, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, Zadvornova Y, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 2011; 17(1): 77– 83.

Rahier J.F., Magro F., Abreu C., Armuzzi A., Ben-Horin S., Chowers Y., Cottone M., de Ridder L., Doherty G., Ehehalt R., Esteve M., Katsanos K., Lees C.W., Macmahon E., Moreels T., Reinisch W., Tilg H., Tremblay L., Veereman-Wauters G., Viget N., Yazdanpanah Y., Eliakim R., Colombel J.F.; European Crohn’s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis. 2014; 8(6): 443– 68

Ran Z., Wu K., Matsuoka K., Jeen Y.T., Wei Sh.Ch., et al. Asian Organization for Crohn’s and colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol. 2020; 36: 637– 45.

Rao M., Ippolito G., Mfinanga S., Ntoumi Fr., Yeboah-Manu D., Vilaplana Cr., Zumla A., Maeurer M. Latent TB infection (LTBI) mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground. Int J Infect Dis. 2019; 80S: S58– 61.

Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012; 18(11): 2034– 42.

Shim T.S.. Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy. Intestnal Res. 2014; 12(1):12-19.

Smith C.H., Anstey A.V., Barker J.N., Burden A.D., Chalmers R.J.G., Chandler D.A., Finlay A.Y., Griffiths C.E.M., Jackson K., McHugh N.J, McKenna K.E., Reynolds N.J., Ormerod A.D. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009; 161(5): 987– 1019.

Song D.J., Tong J.L., Peng J.Ch., Cai Ch.W., Xu X.T., et al. Tuberculosis screening using IGRA and chest computed tomography in patients with inflammatory bowel disease: a retrospective study. J Dig Dis. 2017; 18(1): 23– 30.

Tahiri M., Goh K.L., Abbas Z., Epstein D., Min-Hu Ch., Mulder Ch., Puri A., Schultz M., LeMair A. Digestive tract tuberculosis. World Gastroenterology Organisation Global Guidelines, 2021, р.1-32

Trauer J.M, Moyo N., Tay E.-L., Dale K., Ragonnet R., McBryde E.S., Denholm J.T. Risk of active tuberculosis in the five years following infection…15%? Chest. 2016; 149 (2): 516– 25.

van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS ONE. 2009; 4(12):e8517.

Vortia E., Uko V.E., Yen-Lieberman B., Frawley J., Worley S.E., Danziger-Isakov L., Kaplan B., Mahajan L. Low indeterminate rates associated with use of the QuantiFERON-TB gold in-tube test in children with inflammatory bowel disease on long-term infliximab. Inflamm Bowel Dis. 2018; 24(4): 877– 82.

World health organisation. Global tuberculosis report. Geneva: World Health Organisation; 2021.

World Health Organisation. Latent TB Infection: Updated and consolidated guidelines for programmatic management. Geneva: WHO; 2018. Report No.: WHO/CDS/TB/2018.4.

WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO





Research Article